记者 黄杨子 顾泳 我国扩大免签"朋友圈"后，国际医疗成为不少外籍人士选择来华的一大理由。作为入境第一站的上 海，其医疗资源丰富，部分医院还拥有数十载的国际医疗经验。早在2020年、2023年，上海先后推出非 公和公立医院国际医疗（旅游）试点工作。随着2024年上海市地方标准《国际医疗服务规范》的落地， 上海医疗品牌在国际领域的知名度、含金量持续上升。如今，来华旅游顺道来沪看病，甚至慕名绕大半 个地球前来问诊，正成为更多海外患者的新选择。 社交平台助力来沪求医 上海医疗远不止"性价比高"。随着国内医疗技术在部分专业领域引领世界，上海医疗"金字招牌"影 响力辐射海外。在加拿大温哥华执业20年的华人医生凯文就是"懂行人"。近日，他与妻子带着10岁的女 儿，前往上海交通大学医学院附属瑞金医院胰腺外科求医。在成功接受了高难度的机器人胰腺手术治疗 后，孩子已康复出院。 "女儿在一次意外中被诊断出患有巨大胰腺实性假乳头状瘤这种罕见疾病。"凯文说，夫妻俩不仅带 着女儿看遍了加拿大顶尖专家，还在网上咨询了美国、日本等多国专家，"他们的共识就是这是一台高 难度手术，要完全摘除肿瘤，就要把孩子的脾脏也一起切除"。但凯文接受不了， ...

经济观察网 普瑞眼科2025年业绩预告显示营收预计27.5亿至28.5亿元，净利润亏损5000万至6900万元， 较上年亏损有所收窄。年度报告正式披露后将提供详细财务数据。 业绩经营情况 公司预计2025年度营业收入为27.5亿元至28.5亿元，归属于上市公司股东的净利润亏损5000万元至6900 万元，较2024年亏损额有所收窄。年度报告的正式披露将提供详细财务数据及业务说明。 公司项目推进 公司自2023年以来持续推进"全国连锁化+同城一体化"扩张战略，新开设的十余家眼科医疗机构仍处于 市场培育期。这些新院产生的固定资产折旧、人员薪酬等刚性开支较大，对整体利润形成阶段性压力。 随着营业收入逐步爬升，其规模效应能否驱动亏损进一步收窄值得关注。 业务与技术发展 普瑞眼科在2025年作为全国首批机构引进了卡尔蔡司新一代全飞秒SMILE Pro技术，用于屈光手术，并 重点推广飞秒激光辅助白内障手术等高端解决方案。这些技术引进旨在优化屈光和白内障项目的业务结 构，提升平均客单价。 行业政策与环境 国家组织的人工晶体带量采购政策已在2025年全面执行，叠加医保支付方式改革，对公司白内障项目的 收入和利润空间构成结构性 ...

Market Overview - On February 4, the medical services sector rose by 1.18% compared to the previous trading day, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 32.72, up 8.56%, with a trading volume of 144,400 shares and a transaction value of 464 million [1] - MediX (688202) closed at 63.84, up 3.70%, with a trading volume of 46,200 shares and a transaction value of 289 million [1] - Other notable performers include: - Purui Eye Hospital (301239) at 35.56, up 2.92% [1] - Tigermed (300347) at 64.94, up 2.75% [1] - Kanglong Chemical (300759) at 30.37, up 2.57% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 427 million from institutional investors, while retail investors experienced a net outflow of 439 million [2][3] - Notable net inflows from institutional investors include: - Tigermed (300347) with 158 million [3] - Aier Eye Hospital (300015) with 118 million [3] - WuXi AppTec (603259) with 112 million [3] Individual Stock Capital Flow - Tigermed (300347) had a net institutional inflow of 158 million, accounting for 14.54% of its trading volume [3] - Aier Eye Hospital (300015) had a net institutional inflow of 118 million, representing 12.46% of its trading volume [3] - Other stocks with significant institutional inflows include: - WuXi AppTec (603259) with 112 million [3] - Kanglong Chemical (300759) with 58.6 million [3]

证券代码：301239 证券简称：普瑞眼科 公告编号：2026-002 普瑞眼科医院集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 本次业绩预告相关数据为普瑞眼科医院集团股份有限公司（以下简称"公司"）财务 部门初步测算的结果，未经会计师事务所审计。公司就业绩预告有关事项已与会计师事务 所进行预沟通，双方关于本次业绩预告事项不存在分歧，具体数据以最终审计结果为准。 三、业绩变动原因说明 报告期内，公司整体业绩阶段性承压，但与上年同期相比，营业收入有所增长，亏损 额明显减少，经营发展的整体趋势向好，业绩变动的具体原因如下： （一）外部环境变化的挑战 1、行业竞争持续加剧：报告期内，国内眼科医疗服务市场竞争格局进一步深化，公 司在屈光、视光等核心业务领域的业务量和营业收入有所增长，但激烈的市场竞争对公司 相关项目的毛利率水平构成了挑战。 2、政策性影响的延续：报告期内，国家组织的人 ...

Group 1 - The core viewpoint of the news is that Puri Eye Hospital has shown a slight increase in stock price and has low financing and margin trading balances, indicating a cautious market sentiment towards the company [1] - On January 26, Puri Eye Hospital's stock rose by 0.66%, with a trading volume of 66.66 million yuan. The financing buy amount was 6.065 million yuan, while the financing repayment was 7.893 million yuan, resulting in a net financing outflow of 1.828 million yuan [1] - As of January 26, the total financing and margin trading balance for Puri Eye Hospital was 70.3743 million yuan, with the financing balance accounting for 1.33% of the circulating market value, which is below the 10th percentile level over the past year [1] Group 2 - As of September 30, Puri Eye Hospital had 10,400 shareholders, a decrease of 1.98% from the previous period, while the average circulating shares per person increased by 104.71% to 13,608 shares [2] - For the period from January to September 2025, Puri Eye Hospital achieved an operating income of 2.201 billion yuan, representing a year-on-year growth of 2.99%, and a net profit attributable to shareholders of 16.3491 million yuan, up 3.21% year-on-year [2] - Since its A-share listing, Puri Eye Hospital has distributed a total of 74.5074 million yuan in dividends [3]

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

Core Viewpoint - The company emphasizes that its stock price is influenced by multiple market factors and is committed to monitoring stock price fluctuations while prioritizing investor returns [1] Group 1 - The company stated that if it triggers the conditions for disclosing performance forecasts, it will disclose them within one month after the end of the accounting year [1] - If the conditions are not triggered, the company is not required to disclose performance forecasts [1] - Investors are advised to refer to the announcements published in the company's designated information disclosure media for relevant information [1]

证券代码：301239 证券简称：普瑞眼科 公告编号：2026-001 普瑞眼科医院集团股份有限公司 关于注销部分募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕587号）同意注册，普瑞眼科 医院集团股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A股） 股票37,404,762股，每股面值人民币1.00元，每股发行价格为33.65元，募集资 金总额为1,258,670,241.30元，扣除发行费用（含税）后，实际募集资金净额 为1,098,935,692.69元。 天健会计师事务所（特殊普通合伙）已于2022年06月27日对公司上述募集 资金到位情况进行了审验，并出具了天健验〔2022〕314号《成都普瑞眼科医院 股份有限公司验资报告》。 二、募集资金存放与管理情况 公司首次公开发行股票募集资金投资项目"长春普瑞眼科医院新建项目" 和"哈尔滨普瑞眼科医院改建项目"已达到预定可使用状态，公司于 ...

Group 1 - Core viewpoint: Puri Eye Hospital has seen a continuous increase in stock price, with a 5-day cumulative increase of 5.84% as of January 14, reaching a price of 34.26 yuan per share and a total market capitalization of 5.126 billion yuan [1] - Company overview: Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022. The company provides comprehensive medical services for eye diseases, including diagnosis, treatment, healthcare, and optical services [1] - Revenue composition: The main business revenue is derived from refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), vision projects (13.03%), and other services (1.18%) [1] Group 2 - Shareholder information: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) is among the top ten circulating shareholders of Puri Eye Hospital, having reduced its holdings by 192,500 shares in the third quarter, now holding 2.4 million shares, which is 1.69% of the circulating shares [2] - Fund performance: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has achieved a year-to-date return of 9.61% and a one-year return of 26.99%, ranking 782 out of 8,838 and 4,859 out of 8,089 respectively [2] - Fund manager details: The fund manager, Wan Minyuan, has a tenure of 9 years and 144 days, with a total fund asset size of 5.957 billion yuan and a best return of 149.74% during his tenure [2]

1月11日，深圳普瑞眼科（301239）医院举办"高清视界，不分昼夜——EVO+ ICL(V5)新品发布会"。作 为瑞士STAAR Surgical公司认证的中国内地首批EVO+ ICL(V5)临床应用合作中心，深圳普瑞眼科不仅 带来了前沿晶体技术，更展现了由"双院长、双博导"领衔的中山眼科博士团的医疗实力。 中山眼科博士团护航新技术落地 作为博士团核心成员，徐洋涛团队已于发布会前夕成功实施了院内首批EVO+ ICL(V5)晶体植入手术， 手术效果备受好评。 6.1mm大光区，直击"夜视"痛点 徐洋涛在现场解析了V5晶体的核心突破——中央光学区扩大至6.1mm。这一设计如同给眼睛换上了"更 大的镜头"，有效覆盖暗光下自然放大的瞳孔。这对视觉质量有极高要求的群体尤为重要。 发布会当天，两个不同阶段的患者分别分享术前、术后体验，全方位展示V5技术的落地全貌。王同学 是一位高校学霸，"因为经常需要熬夜查文献、做实验，我对夜间视力要求很高。了解到V5晶体的大光 区优势后，我非常心动。" 在发布会当天，王同学在深圳普瑞眼科完成了全套详细的术前检查。拿到合 格的检查报告后，他表示："检查流程非常细致，徐洋涛医生对数据的解 ...